Literature DB >> 19699284

Preformulation, formulation, and in vivo efficacy of topically applied apomine.

Philip J Kuehl1, Steven P Stratton, Marianne B Powell, Paul B Myrdal.   

Abstract

Apomine is a novel compound that inhibits the mevalonate/isoprenoid pathway of cholesterol synthesis and may prove effective as a skin cancer chemoprevention therapy. This research was focused on the development of a new delivery approach for chemoprevention of melanoma using topically delivered apomine. This included evaluating the effect of several factors on the stability of apomine in solution, utilizing these to develop a topical formulation, and conducting efficacy studies with the developed topical formulation in the TPras mouse model. Preformulation included the influence of pH, buffer species, ionic strength, and organic solvents on the stability of apomine at four different temperatures. Apomine was determined to undergo apparent first-order degradation kinetics for all conditions evaluated. Apomine undergoes base-catalyzed degradation. Less than 15% degradation is observed after >200 days under acidic conditions. Long-term stability studies were performed on two different topical cream formulations and indicate that both formulations are chemically stable for over 1 year at both 4 and 23 degrees C. The efficacy of topically applied apomine, from ethanol and developed 1% cream, was evaluated in vivo against the incidence of melanoma. Regardless of delivery vehicle apomine treatment caused a significant reduction in tumor incidence. Ethyl alcohol application of apomine resulted in a greater tumor incidence reduction when compared to the development cream formulation; however, this difference was not significant.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19699284      PMCID: PMC2783960          DOI: 10.1016/j.ijpharm.2009.08.016

Source DB:  PubMed          Journal:  Int J Pharm        ISSN: 0378-5173            Impact factor:   5.875


  15 in total

1.  Estimation of the aqueous solubility I: application to organic nonelectrolytes.

Authors:  N Jain; S H Yalkowsky
Journal:  J Pharm Sci       Date:  2001-02       Impact factor: 3.534

2.  Phase I pharmacokinetic trial and correlative in vitro phase II tumor kinetic study of Apomine (SR-45023A), a novel oral biphosphonate anticancer drug.

Authors:  D S Alberts; A V Hallum; M Stratton-Custis; D J Garcia; M Gleason-Guzman; S E Salmon; P Santabarbara; E J Niesor; S Floret; C L Bentzen
Journal:  Clin Cancer Res       Date:  2001-05       Impact factor: 12.531

3.  A phase II open-label trial of apomine (SR-45023A) in patients with refractory melanoma.

Authors:  Karl D Lewis; John A Thompson; Jeffrey S Weber; William A Robinson; Steven O'Day; Jose Lutzky; Sewa S Legha; Simon Floret; Francis Ruvuna; Rene Gonzalez
Journal:  Invest New Drugs       Date:  2006-01       Impact factor: 3.850

4.  The mevalonate/isoprenoid pathway inhibitor apomine (SR-45023A) is antiproliferative and induces apoptosis similar to farnesol.

Authors:  J Flach; I Antoni; P Villemin; C L Bentzen; E J Niesor
Journal:  Biochem Biophys Res Commun       Date:  2000-04-02       Impact factor: 3.575

5.  Apomine, an inhibitor of HMG-CoA-reductase, promotes apoptosis of myeloma cells in vitro and is associated with a modulation of myeloma in vivo.

Authors:  Claire M Edwards; Gabrielle Mueller; Anke J Roelofs; Andrew Chantry; Mark Perry; R Graham G Russell; Ben Van Camp; Yves Guyon-Gellin; Eric J Niesor; Craig L Bentzen; Karin Vanderkerken; Peter I Croucher
Journal:  Int J Cancer       Date:  2007-04-15       Impact factor: 7.396

6.  Formulation and in vitro assessment of minoxidil niosomes for enhanced skin delivery.

Authors:  Prabagar Balakrishnan; Srinivasan Shanmugam; Won Seok Lee; Won Mo Lee; Jong Oh Kim; Dong Hoon Oh; Dae-Duk Kim; Jung Sun Kim; Bong Kyu Yoo; Han-Gon Choi; Jong Soo Woo; Chul Soon Yong
Journal:  Int J Pharm       Date:  2009-04-24       Impact factor: 5.875

7.  Effects of perillyl alcohol on melanoma in the TPras mouse model.

Authors:  Maria Lluria-Prevatt; Jeanne Morreale; Jacie Gregus; David S Alberts; Fiona Kaper; Amato Giaccia; Marianne Broome Powell
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2002-06       Impact factor: 4.254

8.  Apomine, a novel hypocholesterolemic agent, accelerates degradation of 3-hydroxy-3-methylglutaryl-coenzyme A reductase and stimulates low density lipoprotein receptor activity.

Authors:  Joseph Roitelman; Danièle Masson; Rachel Avner; Corinne Ammon-Zufferey; Anne Perez; Yves Guyon-Gellin; Craig L Bentzen; Eric J Niesor
Journal:  J Biol Chem       Date:  2003-11-19       Impact factor: 5.157

9.  Apomine enhances the antitumor effects of lovastatin on myeloma cells by down-regulating 3-hydroxy-3-methylglutaryl-coenzyme A reductase.

Authors:  Anke J Roelofs; Claire M Edwards; R Graham G Russell; F Hal Ebetino; Michael J Rogers; Philippa A Hulley
Journal:  J Pharmacol Exp Ther       Date:  2007-04-05       Impact factor: 4.030

10.  Promising agents for chemoprevention of skin cancer.

Authors:  S P Stratton; M S Stratton; D S Alberts
Journal:  Curr Oncol       Date:  2006-10       Impact factor: 3.677

View more
  2 in total

1.  Microemulsion-based oxyresveratrol for topical treatment of herpes simplex virus (HSV) infection: physicochemical properties and efficacy in cutaneous HSV-1 infection in mice.

Authors:  Pattaraporn Sasivimolphan; Vimolmas Lipipun; Garnpimol Ritthidej; Khanidtha Chitphet; Yoshihiro Yoshida; Tohru Daikoku; Boonchoo Sritularak; Kittisak Likhitwitayawuid; Pornpen Pramyothin; Masao Hattori; Kimiyasu Shiraki
Journal:  AAPS PharmSciTech       Date:  2012-08-02       Impact factor: 3.246

2.  Outpatient Follow-up and Secondary Prevention for Melanoma Patients.

Authors:  Ryan G Gamble; Daniel Jensen; Andrea L Suarez; Anne H Hanson; Lauren McLaughlin; Jodi Duke; Robert P Dellavalle
Journal:  Cancers (Basel)       Date:  2010-06-07       Impact factor: 6.639

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.